SUMMARY Debrisoquine and sparteine tests were carried out in 215 random white British subjects. There is a high degree of correlation between the urinary 'metabolic ratios' of the two drugs. New mathematical techniques have been developed (1) to define phenotypes and (2) to identify the genotypes within the dominant phenotype. The members of 15 families were tested with both debrisoquine and sparteine. The results indicate that persons who are 'poor metabolisers' of sparteine are also 'poor metabolisers' of debrisoquine and are autosomal Mendelian recessives.
A genetic polymorphism has been described for the benzylic 4-hydroxylation metabolism of the postganglionic adrenergic blocking hypotensive drug debrisoquine. Poor metabolisers of the compound were autosomal Mendelian recessives, homozygous for an allele with a frequency estimated at 0-30 -~L.SE 0-03 in British whites. ' A polymorphism has also been described for the metabolism of sparteine, an alkaloid which has been used as an anti-arrhythmic and oxytocic drug. One phenotype with a frequency of 0-05 in the German population was unable to metabolise the compound. The other phenotype produced two substances thought to result from N-oxidation. The limited amount of pedigree information previously available suggested that 'non-metabolisers' might be autosomal recessives, homozygous for an allele with a frequency of 0-22.23 This paper presents information to show (1) the manner of inheritance of sparteine metabolism, (2) the relationship between the genetic control of 4-hydroxylation of debrisoquine and the metabolism of sparteine, and (3) the use of improved methods for the analysis of bimodal (and trimodal) frequency distributions.
Methods
The debrisoquine phenotyping test' and the analytical procedure5 were carried out as previously described.
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The sparteine phenotyping test2 was carried out as follows. Subjects who had fasted overnight ingested a 100 mg capsule of sparteine sulphate. They remained in the fasting state for a further 2 hours thereafter and were then allowed normal food and drink. The urine excreted 11 to 13 hours after drug ingestion was collected for analysis. The analytical procedure3 was carried out as described previously. The areas of the gas liquid chromatography peaks for sparteine, 2-dehydrosparteine, and 5-dehydrosparteine were measured. The 'metabolic ratio' was calculated as: area of sparteine peak sum of areas of peaks of 2-dehydrosparteine and 5-dehydrosparteine.
POPULATION SURVEY OF UNRELATED WHITE BRITISH SUBJECTS
A total of 215 healthy unrelated adult subjects (who had given informed consent) were tested with both compounds, with intervals of at least 4 days being allowed between the two tests.
The families studied whose members were tested with the two drugs were obtained by two methods of ascertainment. (1) Some of the families published in a previous report1 were studied because they contained a debrisoquine 'poor metaboliser', found in the population survey of unrelated white British adult subjects. (2) Other families were investigated because they contained a proband who was found in the present population sample of unrelated British 321 white adult subjects to be a non-metaboliser of sparteine. Selected persons were tested with sparteine because they had been found to be poor metabolisers of debrisoquine in previous surveys.
Complete biological repeat tests were performed in several subjects of special interest, and most of these repeated the tests with both drugs on occasions some months apart. (2) Table 2 shows the results of complete biological repeat tests on 35 subjects. Three subjects each performed three debrisoquine tests.
Generally the differences between repeated debrisoquine tests were small, but in some subjects large swings of metabolic ratio were observed. When these few subjects were excluded from consideration repeatability was similar in both phenotypes. This is surprising because the 4-hydroxymetabolite peak in poor metabolisers is much less precisely measurable than in extensive metabolisers, and so the metabolic ratio might vary considerably from time to time. Subjects 10, 27, and 29 underwent an apparent change of phenotype on repeat testing. The Family data
It will be seen that in most instances there is complete correlation between the two polymorphisms, thus agreeing with the view obtained by studying random subjects. However, there are four anomalous subjects: family 2, offspring 1; family 4, offspring 1; family 4, offspring 3; and family 10, offspring 1.
The third of these subjects shows a log1o MR of debrisoquine only just above the division point, so in view of the overlap of the phenotypic distributions 
Discussion
In common with many studies the mathematical arguments are based on normal distributions. Because the number of unequivocal recessives is small, the estimates of the mean, variance, and allele frequency obtained from them are necessarily imprecise, and so the computed antimode might be unreliable. However, in table 1 the computed antimodes for both drugs are seen to be similar for different sets of data.
The procedures for identifying the genotypes within the dominant phenotype are again based upon the normality of the underlying distributions. If this assumption is wrong (for example, owing to skewness), the computed estimates can be imprecise. However, the values of p and q computed from the data for dominants alone agree fairly well with the values of p and q computed from the data from both phenotypes (tables 1 and 5).
The dominance calculations using the method In estimating the parameters of the phenotypes using the present results, the raw data were used. The parameter estimates are computed faster with grouped frequencies than with raw data; the analysis of the published data1 2 was performed on grouped data. However, in separating the dominant genotypes, grouped frequencies were always used because rounding errors arose when the raw data were used.
Some judgement is necessary in deciding upon the truncation points when estimating the parameters of the phenotypes. The phenotype of any observation not in the interval between the truncation points is assumed to be unequivocal. However, the modes of the two distributions must be clearly outside the interval between the truncation points and so the selected interval cannot be too wide.
Despite the difficulties encountered in the computations on the present sparteine and 1980 debrisoquine data,1 it was considered that the two alleles of major effect at one autosomal locus were sufficient to explain most of the observed data on the metabolism of both drugs. Furthermore, it seemed unnecessary, in view of the family data, to assume more complicated models. In particular, the close correlation between the metabolic ratios in random subjects supported this view.
Among family members and selected subjects there were four persons with anomalous results. Possible explanations which may be considered are as follows: (1) Of course, it is clear that these subjects did not represent a random population sample and so must have been selected. In one subject the debrisoquine metabolic ratio was 6 2, but on re-analysing the same specimen of urine, a ratio of 33 was obtained. A complete biological repeat gave a ratio of 62. Otton et all' published an enzymological study in which human liver specimens metabolised sparteine in vitro. Dixon plots revealed that the metabolism of sparteine was competitively inhibited by debrisoquine. Two liver samples were studied but the phenotypes of the two donors were unknown. So while this work suggests strongly that the same enzyme deals with both drugs in the liver, it does not prove that the enzymic mechanism is the same for both drugs in both phenotypes.
The enzymic basis of the polymorphism has been investigated by Davies et al'2 and Kahn et al. '3 These workers determined the in vivo phenotype of subjects from whom liver biopsy material was available. Total hepatic P-450 content was shown not to differ between the phenotypes. Extensive metabolisers were able to form 25 to 50 pmol 4-hydroxydebrisoquine/mg microsomal protein/ minute, whereas one poor metaboliser produced none, so it was suggested that a highly specific form of NADPH requiring hepatic P-450 may be missing in poor metabolisers.
These very elegant enzymological observations suggest most strongly that the same mechanisms are responsible for the oxidation of both sparteine and debrisoquine in the human liver. However, they are based on very few persons (especially poor metabolisers) and so do not rule out the possibility of non-concordance in an occasional subject. 
